We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Issues in the Design of Clinical Trials of Antimycobacterial Drugs for Treating Tuberculosis
News

Issues in the Design of Clinical Trials of Antimycobacterial Drugs for Treating Tuberculosis

Issues in the Design of Clinical Trials of Antimycobacterial Drugs for Treating Tuberculosis
News

Issues in the Design of Clinical Trials of Antimycobacterial Drugs for Treating Tuberculosis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Issues in the Design of Clinical Trials of Antimycobacterial Drugs for Treating Tuberculosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The US Food & Drug Administration (FDA) is hosting a public workshop on July 30-31 2009, to review scientific issues in clinical trial design for treating tuberculosis. The workshop is intended to bring together public health experts, health care providers, academia, and industry to share perspectives on scientific aspects of antimicrobial drug development for tuberculosis, officials note.

The FDA encourages individuals, patient advocates, industry, consumer groups, health care professionals, researchers, and other interested persons to attend this public workshop. There is no charge to attend.

Topics will include considerations in developing clinical trials to study treatments for tuberculosis, including enrollment of patients, effect of antimicrobial treatment, study endpoints, and statistical issues in analysis of results.

In particular: assessing effect size of a new drug in a multi-drug regimen, various endpoints that might be considered to assess drug efficacy for trials of tuberculosis, timing of assessment for efficacy, and extrapolation of safety and efficacy to other subpopulations. The input that is received will help in developing topics for further public discussion.

When and Where:

July 30-31 2009
Crowne Plaza Silver Spring
8777 Georgia Ave
Silver Spring MD 20910

Contact Info:
Christine Moser or Ramou Mauer
Office of Antimicrobial Products
FDA Center for Drug Evaluation & Research
10903 New Hampshire Ave Bldg 22 Rm 6209
Silver Spring MD 20993-0002
Phone 301-796-1300.
Advertisement